MALVERN, Pa., April 25, 2017 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biopolymer-based drugs for the treatment of orphan diseases with an initial focus on cardiopulmonary disorders, today announced that Vice President of Research & Scientific Affairs Jim Ballance, Ph.D., will present preclinical and clinical data on the company’s proprietary elastin-like polypeptide (ELP) biopolymer technology platform in an oral session at the TIDES: Oligonucleotide & Peptide Therapeutics conference to be held April 30 - May 3 at the Manchester Grand Hyatt in San Diego, CA.

Details on the presentation are as follows:

Title: Elastin-Like Polypeptide Biopolymers Enhance the Pharmacology of Therapeutic Peptides
Track: Peptide Discovery, Preclinical and Clinical
Session: Peptides in the Clinic: Lessons Learned
Date / time: Tuesday, May 2, 3:05 - 3:30 p.m. PDT
Location: Cortez Hill

For additional information on the conference, please visit: https://lifesciences.knect365.com/tides/.

About PhaseBio

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing new and improved biotherapeutics for the treatment of orphan diseases, with a focus on cardiopulmonary disorders. The company’s proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which can lead to less-frequent dosing and better patient compliance. PhaseBio's lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension (PAH); the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy; and the treatment of cystic fibrosis. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.

Media Contact:
Laura Bagby, 6 Degrees
(312) 448-8098
lbagby@6degreespr.com 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.